Rena J. Eudy-Byrne, Ph.D.

Senior Scientist II

Rena joined Metrum in November 2015 after completing her Ph.D. in Biomedical Engineering at the University of Connecticut. Her dissertation work included extending a systems pharmacology model of bone and osteoporosis to be relevant for the development new therapies. Part of this work included linking simulated changes in bone mineral density to a hazard model of fracture in a Bayesian framework in order to predict the probability of fracture in osteoporosis patients. Analysis tools for establishing a priori identifiability of target-mediated drug disposition and other indirect response-type models were also part of this larger work. Rena brings 5 years of industry experience to the team, including work in preclinical development in metabolic systems and neuroscience and using systems pharmacology models to inform clinical decisions.

Recent publications by this scientist

Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections.

December 6, 2024

Presented at ACoP 2024. In this analysis aimed to evaluate the ability to estimate robust population PD parameters and a landmark endpoint in different scenarios. In the primary workflow different levels of missing PK data were tested. Additionally, varying degrees of of individual-level and residual variability were tested. Finally, scenarios with smaller populations were tested. In all scenarios, PD parameters and endpoints could be estimated with adequate accuracy and precision.

Download PDF

Adaptive Buprenorphine Dose Simulations In Infants with NOWS (Neonatal Opioid Withdrawal Syndrome).

April 3, 2024

Presented by Dr. Rena Byrne at the 13th Annual Indiana CTSI Disease and Therapeutic Response Modeling Symposium, February 2024.
View presentation recording.

Download PDF

Integrated Population Pharmacokinetic Analysis of Conjugated and Unconjugated Payload of Patritumab Deruxtecan in Cancer Patients

November 14, 2023

Presented at ACoP14. Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor (HER3)-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload (DXd). The drug-to-antibody ratio is approximately 8. HER3-DXd is currently being investigated as an anticancer agent in several phase 1-3 clinical studies in breast cancer (BC) and nonsmall cell lung cancer ( NSCLC) patients.

Download PDF